The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Abstract
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. RESULTS: Irinotecan was investigated as second-line chemotherapy after prior treatment with fluorouracil (FU)-based regimens in two large randomized phase III trials comparing irinotecan with either best supportive care or an infusional FU/leucovorin (LV) regimen. The outcomes of these trials established irinotecan as the standard therapy in the second-line treatment of colorectal cancer. The therapeutic value of irinotecan in the first-line treatment of metastatic colorectal cancer was investigated in two large randomized phase III trials comparing the combination of irinotecan and FU/LV with FU/LV alone. Both trials demonstrated significant superior efficacy for the combination of irinotecan and FU/LV in terms of response rate, median time to disease progression, and median survival time. Consequently, the combination of irinotecan and FU/LV has been approved as first-line chemotherapy for patients with metastatic colorectal cancer and constitutes the reference therapy against which other treatment options must be tested in the future. CONCLUSION: In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Wang, J. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.003223 · Cited by 1,832
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Cited by
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
“Irinotecan causes severe diarrhoea in up to 40% of patients, requiring dose reduction and, in many cases, premature termination of the drug 42 .”
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Köhne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Reichardt, P., Rückle-Lanz, H., Frickhofen, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.546 · Cited by 331
Self-citationIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602042 · Cited by 315
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A., & Gamelin, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0548 · Cited by 276
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Developing a metagenomic view of xenobiotic metabolism
Haiser, H. J., & Turnbaugh, P. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.07.009 · Cited by 186
“The drug is delivered intravenously and then metabolized by carboxylesterases in tissue and serum to form the active SN-38; the cytotoxic effects of SN-38 are mediated though the inhibition of topoisomerase I in tumor cells [67].”
BackgroundA phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.016 · Cited by 57
Bhonde, M. R., Hanski, M.-L., Notter, M., Gillissen, B. F., Daniel, P. T., Zeitz, M., & Hanski, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209017 · Cited by 47
“Colorectal carcinomas respond to the standard first-line chemotherapy (5FUþ folic acidþ irinotecan) in about 41% of cases (Vanhoefer et al., 2001).”
BackgroundHyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
“are frequently used in chemotherapeutic treatment of gastrointestinal (GI) cancers, including colorectal cancer.(3-19) In most cases, two or more of these drugs are combined, resulting in greater efficacy.”
BackgroundPLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan
Emami, J., Maghzi, P., Hasanzadeh, F., Sadeghi, H., Mirian, M., & Rostami, M. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1340950 · Cited by 36
Effects of methimazole on the elimination of irinotecan
van der Bol, J. M., Visser, T. J., Loos, W. J., de Jong, F. A., Wiemer, E. A. C., van Aken, M. O., Planting, A. S., Schellens, J. H., Verweij, J., & Mathijssen, R. H. J. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1414-x · Cited by 9
Metadata
- Authors
- Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-01
- Volume
- 19
- Issue
- 5
- Pages
- 1501-1518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1927999720
- Cited by
- 326
- References
- 106
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.